Voltar
Revisão Acesso aberto Revisado por pares
BIBTEX RIS

Visceral leishmaniasis: immunology and prospects for a vaccine

2011; Elsevier BV; Volume: 17; Issue: 10 Linguagem: Inglês

10.1111/j.1469-0691.2011.03610.x

ISSN

1469-0691

Autores

Paul M. Kaye, Toni Aebischer,

Tópico(s)

Parasites and Host Interactions

Resumo

Human visceral leishmaniasis (HVL) is the most severe clinical form of a spectrum of neglected tropical diseases caused by protozoan parasites of the genus Leishmania. Caused mainly by L. donovani and L. infantum/chagasi, HVL accounts for more than 50 000 deaths every year. Drug therapy is available but costly, and resistance against several drug classes has evolved. Here, we review our current understanding of the immunology of HVL and approaches to and the status of vaccine development against this disease.

Referência(s)